Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Osteoporosis Reports
Erschienen in: Current Osteoporosis Reports 1/2017

21.01.2017 | Bone and Diabetes (A Schwartz and P Vestergaard, section editors)

Is Diabetic Skeletal Fragility Associated with Microvascular Complications in Bone?

verfasst von: Roberto Jose Fajardo

Erschienen in: Current Osteoporosis Reports | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The objective of this literature review is to determine whether there are indications that microvascular complications occur in diabetic bone. Evidence definitively linking diabetic skeletal fragility with microvascular complications in bone remains elusive.

Recent Findings

Circumstantial evidence, some recent and some lost to time, suggests that atherosclerotic vascular diseases such as peripheral arterial disease cause poor blood perfusion of bone and subsequent hypoxia and contribute to low bone density and high cortical porosity, patterns similar to some recently observed in diabetic subjects. Evidence also exists to suggest that potentially anti-angiogenic conditions, such as impaired vascular endothelial growth factor (VEGF) signaling, predominate in diabetic bone.

Summary

Microvascular complications may contribute, in part, to diabetic skeletal fragility but data supporting this interpretation are primarily circumstantial at this time. This review highlights gaps in our knowledge and hopefully spurs further discussions and research on this topic.
Literatur
1.
Bonds DE et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404–10.CrossRefPubMed
2.
Janghorbani M et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505.CrossRefPubMed
3.
Martinez-Laguna D et al. Incident type 2 diabetes and hip fracture risk: a population-based matched cohort study. Osteoporos Int. 2015;26(2):827–33.CrossRefPubMed
4.
Fan Y et al. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016;27(1):219–28.CrossRefPubMed
5.
Looker AC, Eberhardt MS, Saydah SH. Diabetes and fracture risk in older U.S. adults. Bone. 2016;82:9–15.CrossRefPubMed
6.
Ottenbacher KJ et al. Diabetes mellitus as a risk factor for hip fracture in Mexican American older adults. J Gerontol A Biol Sci Med Sci. 2002;57(10):M648–53.CrossRefPubMed
7.
Kilpadi KL et al. Type 2 diabetes is associated with vertebral fractures in a sample of clinic- and hospital-based Latinos. J Immigr Minor Health. 2014;16(3):440–9.CrossRefPubMed
8.
American Diabetes Association. Fast facts. Data and statistics about diabetes, 2014.
9.
International Diabetes Federation. IDF Diabetes Atlas, 2015.
10.
Hernandez RK et al. Patient-related risk factors for fracture-healing complications in the United Kingdom General Practice Research Database. Acta Orthop. 2012;83(6):653–60.CrossRefPubMedPubMedCentral
11.
Semel J et al. Predictors of outcome following hip fracture rehabilitation. PM&R. 2010;2(9):799–805.
12.
13.
Bass E, French DD, Bradham DD. A national perspective of Medicare expenditures for elderly veterans with hip fractures. J Am Med Dir Assoc. 2008;9(2):114–9.CrossRefPubMed
14.
15.
Wilmot EG et al. Type 2 diabetes in younger adults: the emerging UK epidemic. Postgrad Med J. 2010;86(1022):711–8.CrossRefPubMed
16.
Kao WH et al. Type 2 diabetes is associated with increased bone mineral density in Mexican-American women. Arch Med Res. 2003;34(5):399–406.CrossRefPubMed
17.
Ma L et al. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012;27(5):319–32.CrossRefPubMedPubMedCentral
18.
Prieto-Alhambra D et al. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. J Bone Miner Res. 2012;27(2):294–300.CrossRefPubMed
19.
20.
21.
Bailey AJ, Paul RG, Knott L. Mechanisms of maturation and ageing of collagen. Mech Ageing Dev. 1998;106(1–2):1–56.CrossRefPubMed
22.
23.
Karim L, Bouxsein ML. Effect of type 2 diabetes-related non-enzymatic glycation on bone biomechanical properties. Bone. 2016;82:21–7.CrossRefPubMed
24.
Vashishth D et al. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone. 2001;28(2):195–201.CrossRefPubMed
25.
Farr, J.N., et al., In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res, 2013;29(4):787–95.
26.
27.
28.
Viguet-Carrin S et al. An in vitro model to test the contribution of advanced glycation end products to bone biomechanical properties. Bone. 2008;42(1):139–49.CrossRefPubMed
29.
Hofmann B et al. Relationship between cardiac tissue glycation and skin autofluoresence in patients with coronary artery disease. Diab and Metabol. 2014;41(5):410–5.
30.
Fessel G et al. Advanced glycation end-products reduce collagen molecular sliding to affect collagen fibril damage mechanisms but not stiffness. PLoS One. 2014;9(11), e110948.CrossRefPubMedPubMedCentral
31.
Saito M et al. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006;17(10):1514–23.CrossRefPubMed
32.
Ivers RQ et al. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care. 2001;24(7):1198–203.CrossRefPubMed
33.
Viegas M et al. Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications. J Diabetes Complications. 2011;25(4):216–21.CrossRefPubMed
34.
• Burghardt AJ et al. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95(11):5045–55. This is the first paper to show that diabetic bone tissue is characterized by cortical porosity.
35.
Patsch JM et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013;28(2):313–24.CrossRefPubMedPubMedCentral
36.
Heilmeier U et al. Cortical bone laminar analysis reveals increased midcortical and periosteal porosity in type 2 diabetic postmenopausal women with history of fragility fractures compared to fracture-free diabetics. Osteoporos Int. 2016;27(9):2791–802.CrossRefPubMed
37.
• Lim Y et al. Association of bone mineral density and diabetic retinopathy in diabetic subjects: the 2008–2011 Korea National Health and Nutrition Examination Survey. Osteoporos Int. 2016;27(7):2249–57. This paper reports on a large epidemiological study showing that low BMD in diabetic women is associated with a long disease duration and diabetic retinopathy.
38.
• Thompson B, Towler DA. Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol. 2012;8(9):529–43. This is an excellent review of the complex interactions of the bone-vascular axis.
39.
Zelzer E et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development. 2002;129(8):1893–904.PubMed
40.
Maes C et al. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev. 2002;111(1–2):61–73.CrossRefPubMed
41.
• Hu K, Olsen BR. Osteoblast-derived VEGF regulates osteoblast differentiation and bone formation during bone repair. J Clin Invest. 2016;126(2):509–26. This study comprehensively reports on the roles of osteoblast-expressed VEGF-A in a bone healing model. It provides compelling new information on its autocrine and paracrine effects in bone healing.
42.
Street J et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A. 2002;99(15):9656–61.CrossRefPubMedPubMedCentral
43.
Wang Y et al. The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest. 2007;117(6):1616–26.CrossRefPubMedPubMedCentral
44.
•• Prisby RD et al. Aging reduces skeletal blood flow, endothelium-dependent vasodilation, and NO bioavailability in rats. J Bone Miner Res. 2007;22(8):1280–8. A seminal paper showing that skeletal blood flow decreases with age and provides evidence that diminished vasodilation resulting from limited nitric oxide availability is a root cause.
45.
McCarthy I. The physiology of bone blood flow: a review. J Bone Joint Surg Am. 2006;88 (Suppl 3):4–9.
46.
Cowin SC, Cardoso L. Blood and interstitial flow in the hierarchical pore space architecture of bone tissue. J Biomech. 2015;48(5):842–54.CrossRefPubMed
47.
•• Brookes M. The vascular reaction of tubular bone to ischaemia in peripheral occulusive vascular disease. J Bone Joint Surg (Br). 1960;42(1):110–25. This histological study of human tibiae was one of the first to report that atherosclerotic disease was associated with dramatic changes in bone structure, most likely due to poor blood perfusion. The patterns revealed by Brookes are similar to those observed in diabetic patients with and without vascular disease.
48.
Tanko LB et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005;20(11):1912–20.CrossRefPubMed
49.
• Matsumoto T et al. Three-dimensional cortical bone microstructure in a rat model of hypoxia-induced growth retardation. Calcif Tissue Int. 2011;88(1):54–62. This paper shows that hypoxia in long bones results in structural changes such as cortical porosity that results from efforts to revascularize the bone tissue. This work corroborates Brookes’ early work in an experimental animal model.
50.
Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: a critical review of the evidence. JAMA. 2003;290(7):932–40.CrossRefPubMed
51.
Brookes M. Sequelae of experimental partial ischaemia in long bones of the rabbit. J Anat. 1960;94(Pt 4):552–61.PubMedPubMedCentral
52.
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116(9):1509–26.CrossRefPubMed
53.
54.
Simard E et al. Receptor for advanced glycation end-products signaling interferes with the vascular smooth muscle cell contractile phenotype and function. PLoS One. 2015;10(8), e0128881.CrossRefPubMedPubMedCentral
55.
•• Shanbhogue VV et al. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur J Endocrinol. 2016;174(2):115–24. This paper is very important because it demonstrates with high-resolution CT imaging that cortical porosity is associated with a microvascular disease diagnosis.
56.
Yu EW et al. Defects in cortical microarchitecture among African-American women with type 2 diabetes. Osteoporos Int. 2015;26(2):673–9.CrossRefPubMed
57.
Paccou J et al. Bone microarchitecture in men and women with diabetes: the importance of cortical porosity. Calcif Tissue Int. 2016;98(5):465–73.CrossRefPubMed
58.
Chen YW et al. High prevalence of lower extremity peripheral artery disease in type 2 diabetes patients with proliferative diabetic retinopathy. PLoS One. 2015;10(3), e0122022.CrossRefPubMedPubMedCentral
59.
Oikawa A et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol. 2010;30(3):498–508.CrossRefPubMed
60.
Spinetti G et al. Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ Res. 2013;112(3):510–22.CrossRefPubMed
61.
Orlandi A et al. Long-term diabetes impairs repopulation of hematopoietic progenitor cells and dysregulates the cytokine expression in the bone marrow microenvironment in mice. Basic Res Cardiol. 2010;105(6):703–12.CrossRefPubMed
62.
Tepper OM et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation. 2002;106(22):2781–6.CrossRefPubMed
63.
Costa PZ, Soares R. Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox. Life Sci. 2013;92(22):1037–45.CrossRefPubMed
64.
Roca F et al. Glycation: the angiogenic paradox in aging and age-related disorders and diseases. Ageing Res Rev. 2014;15:146–60.CrossRefPubMed
65.
Simo R et al. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2(1):71–98.CrossRefPubMed
66.
Neufeld G et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13(1):9–22.PubMed
67.
Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature. 2005;438(7070):937–45.CrossRefPubMed
68.
Clarkin CE, Gerstenfeld LC. VEGF and bone cell signalling: an essential vessel for communication? Cell Biochem Funct. 2013;31(1):1–11.CrossRefPubMed
69.
Wang S et al. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7. Proc Natl Acad Sci U S A. 2008;105(22):7738–43.CrossRefPubMedPubMedCentral
70.
Grover TR et al. Vascular endothelial growth factor causes pulmonary vasodilation through activation of the phosphatidylinositol-3-kinase-nitric oxide pathway in the late-gestation ovine fetus. Pediatr Res. 2002;52(6):907–12.CrossRefPubMed
71.
72.
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–76.CrossRefPubMed
73.
Barleon B et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis. 2001;4(2):143–54.CrossRefPubMed
74.
Saito T et al. VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing. FEBS Lett. 2013;587(14):2179–85.CrossRefPubMed
75.
Zhang F et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A. 2009;106(15):6152–7.CrossRefPubMedPubMedCentral
76.
77.
Ben-Av P et al. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995;372(1):83–7.CrossRefPubMed
78.
Ishida A et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol. 2001;188(3):359–68.CrossRefPubMed
79.
Deckers MM et al. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology. 2000;141(5):1667–74.CrossRefPubMed
80.
Prasadam I et al. Osteocyte-induced angiogenesis via VEGF-MAPK-dependent pathways in endothelial cells. Mol Cell Biochem. 2014;386(1–2):15–25.CrossRefPubMed
81.
Cheung WY et al. Osteocyte apoptosis is mechanically regulated and induces angiogenesis in vitro. J Orthop Res. 2011;29(4):523–30.CrossRefPubMed
82.
Al-Dujaili SA et al. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro. J Cell Biochem. 2011;112(9):2412–23.CrossRefPubMed
83.
Zhang Q et al. VEGF-C, a lymphatic growth factor, is a RANKL target gene in osteoclasts that enhances osteoclastic bone resorption through an autocrine mechanism. J Biol Chem. 2008;283(19):13491–9.CrossRefPubMedPubMedCentral
84.
Yang Q et al. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol. 2008;27(7):589–99.CrossRefPubMed
85.
Makino N et al. High serum TNF-alpha level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells. J Diabetes Complications. 2005;19(6):347–55.CrossRefPubMed
86.
Ai-Aql ZS et al. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res. 2008;87(2):107–18.CrossRefPubMedPubMedCentral
87.
Botusan IR et al. Stabilization of HIF-1alpha is critical to improve wound healing in diabetic mice. Proc Natl Acad Sci U S A. 2008;105(49):19426–31.CrossRefPubMedPubMedCentral
88.
• Thangarajah H et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A. 2009;106(32):13505–10. This paper reports that hyperglycemia impairs the transactivation of hypoxia-inducible factor 1 alpha (HIF-1α). This may be the mechanism that causes decreased VEGF-A expression in osteoblasts exposed to chronic hyperglycemia.
89.
•• Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem. 2006;99(2):411–24. Seminal paper that demonstrates the impact of chronic hyperglycemia on osteoblasts. One outcome is decreased VEGF-A expression, thus diminishing the pro-angiogenic potential of the bone microenvironment.
90.
Coe LM et al. The bone marrow microenvironment contributes to type I diabetes induced osteoblast death. J Cell Physiol. 2011;226(2):477–83.CrossRefPubMed
91.
Rashid G et al. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int. 2004;66(3):1099–106.CrossRefPubMed
92.
Vestergaard P, Rejnmark L, Mosekilde L. Are antiresorptive drugs effective against fractures in patients with diabetes? Calcif Tissue Int. 2011;88(3):209–14.CrossRefPubMed
93.
Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107.CrossRefPubMed
94.
Esser N et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141–50.CrossRefPubMed
95.
Sharma R et al. Caspase-2 maintains bone homeostasis by inducing apoptosis of oxidatively-damaged osteoclasts. PloS one. 2014;9(4):e93696.
96.
97.
Kapoor D et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.CrossRefPubMed
98.
99.
Movahed A et al. Reduced serum osteocalcin concentrations are associated with type 2 diabetes mellitus and the metabolic syndrome components in postmenopausal women: the crosstalk between bone and energy metabolism. J Bone Miner Metab. 2012;30(6):683–91.CrossRefPubMed
100.
Ardawi MS et al. Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013;56(2):355–62.CrossRefPubMed
101.
Alikhani M et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone. 2007;40(2):345–53.CrossRefPubMed
102.
Zhang Y, Yang JH. Activation of the PI3K/Akt pathway by oxidative stress mediates high glucose-induced increase of adipogenic differentiation in primary rat osteoblasts. J Cell Biochem. 2013;114(11):2595–602.CrossRefPubMed
103.
Yeap BB et al. Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men. J Clin Endocrinol Metab. 2015;100(1):63–71.CrossRefPubMed
104.
Yamamoto M et al. Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(4):1277–84.CrossRefPubMed
105.
O’Sullivan EP et al. Osteoprotegerin is higher in peripheral arterial disease regardless of glycaemic status. Thromb Res. 2010;126(6):e423–7.CrossRefPubMed
106.
Niu Y et al. Association of plasma osteoprotegerin levels with the severity of lower extremity arterial disease in patients with type 2 diabetes. BMC Cardiovasc Disord. 2015;15:86.CrossRefPubMedPubMedCentral
107.
Yamamoto M et al. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(3):1013–9.CrossRefPubMed
108.
Leslie WD et al. Biphasic fracture risk in diabetes: a population-based study. Bone. 2007;40(6):1595–601.CrossRefPubMed
109.
Metadaten
Titel
Is Diabetic Skeletal Fragility Associated with Microvascular Complications in Bone?
verfasst von
Roberto Jose Fajardo
Publikationsdatum
21.01.2017
Verlag
Springer US
Erschienen in
Current Osteoporosis Reports / Ausgabe 1/2017
Print ISSN: 1544-1873
Elektronische ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-017-0341-8

Weitere Artikel der Ausgabe 1/2017

Current Osteoporosis Reports 1/2017 Zur Ausgabe

Biomechanics (M Silva and K Jepsen, Section Editors)

Physical Activity for Strengthening Fracture Prone Regions of the Proximal Femur

Craniofacial Skeleton (G Roberts, Section Editor)

Genetic Disorders of Dental Development: Tales from the Bony Crypt

Skeletal Development (P Trainor and K Svoboda, Section Editors)

Connexin43 and the Intercellular Signaling Network Regulating Skeletal Remodeling

Kidney and Bone (S Moe and I Salusky, Section Editors)

The Role of TGFβ in Bone-Muscle Crosstalk

Biomechanics (M Silva and K Jepsen, Section Editors)

Clinical Evaluation of Bone Strength and Fracture Risk

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

16.04.2024 | Spondylitis ankylosans | Nachrichten

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

15.04.2024 | Knie-TEP | Nachrichten

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

11.04.2024 | Spondyloarthritiden | Nachrichten

Zwei neue Alternativen zu TNF-Inhibitoren bei axSpA

11.04.2024 | Rückenschmerzen | Nachrichten

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen
weitere anzeigen

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise